Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Arvinas

Biotech Arvinas Stock Earns 82 RS Rating

Arvinas sees its Relative Strength Rating hit the 80-plus level.

Investors Business Daily

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

Biotech stocks heated up Thursday as Novartis scooped up a licensing pact with Arvinas and Janux was said to be exploring strategic options.

Investors Business Daily

5 Biotechs with $1 Billion in Cash

5 Biotechs with $1 Billion in Cash

Worried about a recession? These cashed-up biotech stocks aren't sweating it.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

7 Analysts Have This to Say About Arvinas

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

Analyst Ratings for Arvinas

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022

Arvinas: Q1 Earnings Insights

Arvinas (NASDAQ:ARVN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

inkl

Read news from The Economist, FT, and more,
with one subscription

What 6 Analyst Ratings Have To Say About Arvinas

What 6 Analyst Ratings Have To Say About Arvinas

Over the past 3 months, 6 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

Expert Ratings For Arvinas

Expert Ratings For Arvinas

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022

Arvinas Earnings Perspective: Return On Capital Employed

Arvinas Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Arvinas (NASDAQ:ARVN) reported Q4 sales of $26.30 million. Earnings fell to a loss of $53.00 million, resulting in a 13.35% decrease from last quarter.

Where Arvinas Stands With Analysts

Where Arvinas Stands With Analysts

Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:

Organisations

Intuitive Surgical

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play